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Abstract
Objective
To compare synthetic oxytocin infusion regimens used during labour, calculate the Interna-
tional Units (IU) escalation rate and total amount of IU infused over eight hours.
Design
Observational study
Setting
Twelve countries, eleven European and South Africa.
Sample
National, regional or institutional-level regimens on oxytocin for induction and augmentation
labour
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Methods
Data on oxytocin IU dose, infusion fluid amount, start dose, escalation rate and maximum
dose were collected. Values for each regimen were converted to IU in 1000ml diluent. One
IU corresponded to 1.67μg for doses provided in grams/micrograms. IU hourly dose
increase rates were based on escalation frequency. Cumulative doses and total IU amount
infused were calculated by adding the dose administered for each previous hour. Main Out-
come Measures Oxytocin IU dose infused
Results
Data were obtained on 21 regimens used in 12 countries. Details on the start dose, escala-
tion interval, escalation rate and maximum dose infused were available from 16 regimens.
Starting rates varied from 0.06 IU/hour to 0.90 IU/hour, and the maximum dose rate varied
from 0.90 IU/hour to 3.60 IU/hour. The total amount of IU oxytocin infused, estimated over
eight hours, ranged from 2.38 IU to 27.00 IU, a variation of 24.62 IU and an 11-fold
difference.
Conclusion
Current variations in oxytocin regimens for induction and augmentation of labour are inexpli-
cable. It is crucial that the appropriate minimum infusion regimen is administered because
synthetic oxytocin is a potentially harmful medication with serious consequences for women
and babies when inappropriately used. Estimating the total amount of oxytocin IU received
by labouring women, alongside the institution’s mode of birth and neonatal outcomes, may
deepen our understanding and be the way forward to identifying the optimal infusion
regimen.
Introduction
Infused synthetic oxytocin (Syntocinon1) [1] is one of the most widely used medications in
labouring women. However, almost 70 years after it was first used in clinical practice [2] there
is no agreement on the optimal infusion regimen to use during induction or augmentation of
labour. Guideline recommendations vary [3–6] and debate about the risks and benefits of
using high or low dose oxytocin regimens for induction of labour at term continues [7]. When
labour is induced, discontinuing infused oxytocin after the onset of the active phase has no
effect on the risk of having a caesarean section [8]. When labour onset is spontaneous, oxyto-
cin administration for treating delayed progress, compared to delayed or no oxytocin adminis-
tration, reduces the time to birth duration by approximately two hours but not the number of
caesarean sections performed [9]. The authors concluded that a drug used for over 40 years to
reduce the need for operative delivery was still not proven to be effective in its original primary
role i.e., prevention of caesarean section [9]. While the effects of infused oxytocin on the uterus
are not understood fully, one study found a decrease in the concentration of myometrial recep-
tor binding sites and messenger RNA (mRNA), indicating that receptor desensitisation occurs
[10]. A more recent study on levels of amniotic fluid lactate (AFL) just before augmentation
with oxytocin found that low levels may aid the decision to continue augmentation but that
high levels were predictive of an increased risk of caesarean section [11]. While more trials are
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needed on the most effective dose, escalation rate and method of administration, pulsed or
continuous, optimising the dose of oxytocin infused is important. The pulsatile pattern of oxy-
tocin release, with increasing pulse frequency, observed during spontaneous labour is of physi-
ologic significance [12, 13]: short lasting peaks start to occur at term and increase in frequency
and size during labour, to a maximum of three pulses/10 minutes [14]. Infused oxytocin causes
a flat pattern of release and a different pattern of uterine contractions to that seen during phys-
iological labour. Contractions become irregular, more frequent, longer, and more painful, and
may lead to hyperstimulation and compromised blood flow to the fetus. This abnormal con-
traction pattern increases the signalling in sensory nerves from the uterus, which leads to
increased pain and stress levels in the mother [13].
When oxytocin is infused in doses up to 10 mU/min (0.6 IU/hour) plasma levels of oxyto-
cin are within the range of oxytocin levels in physiological birth, around 40 picograms (pg)/
ml. Oxytocin infusions influence the plasma levels of oxytocin in a dose dependent way and
doubling the dose leads to doubling of the oxytocin levels. This means that when oxytocin is
infused at a rate of 1.2 IU/hour the plasma oxytocin levels will be twice as high as during an
infusion of 0.6 IU/hour or during normal physiological labour [12, 15, 16]. In addition, infused
oxytocin does not cross the blood brain barrier and does not influence brain function in the
same way as endogenous oxytocin [13]. Synthetic oxytocin is also a high-alert medication [17]
that can have several adverse side effects [8, 9, 18], and it is implicated in obstetric claims in
several countries [19–21]. Symptoms associated with over dose include uterine hyperstimula-
tion and fetal heart rate changes [8, 9], meconium staining of the amniotic fluid, fetal asphyxia,
placental abruption, amniotic fluid embolism and water intoxication [1]. Common maternal
adverse effects, i.e., affecting 1 in 100 women, reported during the drug testing trials include
headache, tachycardia or bradycardia and nausea and/or vomiting. Rare adverse effects, i.e.,
affecting 1 in 10,000 women, include anaphylactic reaction with dyspnoea, hypotension and
skin rash [1]. Because of the impact on the physiological process of labour, and the plethora of
potential side effects, we sought to estimate the total IU dose of synthetic oxytocin that would
be infused over eight hours of labour, based on the start, escalating and maximum doses in
available guidelines. This information is important in the context of over-medicalisation of
normal pregnancy and birth [22] and because considerable proportions of labouring women
worldwide receive infused oxytocin.
Aim
To compare the guidelines on oxytocin infusion regimens used during labour in 12 countries
and calculate the total amount of oxytocin IU received over an eight-hour period.
Materials and methods
The study was conducted in 2017/18 as part of the COST Action IS1405 (BIRTH) (2014–2018)
(https://www.cost.eu/actions/IS1405/BIRTH), a European-based network which aimed to
advance scientific knowledge of the normal physiology of labour and birth. An email seeking
expressions of interest in the review was sent to the 51 registered members of the Action’s
working group 4 who were based in 20 countries. To take part in the review, members needed
knowledge of and access to their country’s/region’s/local institution’s maternity services guide-
line on use of intrapartum oxytocin for induction and acceleration of labour. There were no
exclusion criteria. A total of 18 members from 12 countries expressed an interest in taking part
in the review.
A core group developed a data collection form based on the criteria used in the Irish clinical
practice guideline on oxytocin to induce or accelerate labour [4]. The form was then sent to
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the 18 participants for content validation and review. Subsequently, one item was included on
the persons responsible for developing the guideline (obstetricians, midwives, users) and the
final form contained 24 items (Table 1) (Available as a spreadsheet in S1 Data). Data collected
included the oxytocin IU dose, type and amount of infusion fluid, start dose and escalation
rate (ml/hour or IU/hour) (Table 1 and S1 Data).
Ethics
As the study was a review of available national, regional and/or local regimens on intrapartum
oxytocin administration, ethics committee approval was not required. Data collected included
the country’s name and type of guideline, national, regional or institution-level, and institu-
tion-level guidelines were identified as ‘institution 1, 2 etc.’ but not by name. No participant or
individual-level data were collected. Written consent was not required. Participants volun-
teered to provide information requested. Eighteen members from 12 countries participated in
the present study: 10 high-income and one upper-middle income European countries, and
South Africa, a middle-income country. When members provided data on several guidelines
or from several institutions in a country, we reported on the maximum and minimum regi-
mens used in that country.
Analysis
Data analysis broadly followed the approach used by Helbig et al [23]. Values for each regimen
were converted to International Units (IU) in 1000ml of diluent, to obtain a common denomi-
nator for further dose calculations. One IU corresponded to 1.67μg for doses provided in
grams or micrograms. The escalation rate (IU per hour) was calculated based on the frequency
of escalation (escalation interval), being either 15, 20, 30 minutes. If millilitres (mls) were
given for the rate increase, IU per hour was calculated by dividing the dose in the diluent (IU
per 1000 mls) by 1000 (to obtain IU per ml) and then multiplied by the amount of mls esca-
lated per hour. Using this escalation rate, the IU dose increase per hour could be calculated for
each regimen, for a hypothetical eight-hour period, bearing in mind that escalation stopped
when the maximum prescribed dose was reached or when effective uterine contractions were
Table 1. Data collection form.
Country Is there a national
guideline?
Year Oxytocin dose Infusion fluid Amount Start dose Escalation rate
Maximum dose Is there a separate
guideline for
induction and
acceleration
(augmentation) of
labour?
Is oxytocin
titrated with
uterine
contractions?
How often are
uterine
contractions
recorded?
Does guideline
differ (dose,
escalation rate,
uterine activity,
stage of labour
(first or second
stage)) for
nulliparous
women?
Does guideline differ
(dose, escalation rate,
uterine activity, stage of
labour (first or second
stage)) for multiparous
women?
Does guideline
differ (dose,
escalation rate,
uterine activity,
stage of labour
(first or second
stage)) for
women with a
uterine scar?
Does guideline differ
(dose, escalation rate,
uterine activity, stage
of labour (first or
second stage)) for
women with a twin
pregnancy?
Does guideline
differ (dose,
escalation rate,
uterine activity,
stage of labour
(first or second
stage)) for women
in pre-term
labour?
Do local guidelines
differ from national
guidelines? (If yes,
give example)
Variations in
guidelines
Who can start
oxytocin
infusion?
Criteria for
starting oxytocin
infusion
Contraindication to use Criteria for
stopping
oxytocin infusion
Who was involved in
the development of
the guideline?
(Obstetricians,
midwives, users)
https://doi.org/10.1371/journal.pone.0227941.t001
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achieved. Cumulative doses were calculated by adding the dose administered for each hour to
the doses administered over the previous hour/s, then the total dose of oxytocin IU infused
over an eight-hour period was calculated. Calculations were performed by two authors (KM,
AB), then checked and verified by another three authors (BB, IK, SG-B).
Results
Guideline content
Data collection forms on 21 regimens were received from 12 countries. A summary of regi-
mens is presented in Table 2 and the detailed descriptions are in S2 Data.
Data on national guidelines were obtained from Denmark (for primiparous women only),
Ireland, Norway, Sweden and South Africa (S2 Data). Data on two or more regimens, in use in
different regions or institutions, were received from Austria, Belgium, Cyprus, Germany, Ire-
land, Poland and Switzerland (German and Italian-speaking regions and French-speaking
region). When these regimens were different, we used data on the minimum and maximum
regimens for calculations. Belgium’s guidelines were from one institution and the national
food and drug administration guidance but resulted in the same regimens. The Austrian data
were from three institutions; the Irish data were from the national guideline and from one
institution that used a different regimen; the Swiss data were from German and Italian-speak-
ing regions and the French-speaking region. German data were from 35 university hospitals
[23] and we included only data on the minimum and maximum regimens in this analysis.
Apart from Denmark’s regimen which was for augmentation of labour only, all other regimens
were the same for both induction and augmentation of labour and almost all stated that the
infusion should be titrated with uterine contractions.
Criteria for use
Denmark’s regimen was for primiparous women only, and Ireland’s regimen differed for pri-
miparous and multiparous women (S2 Data). Most regimens had different criteria on starting,
stopping and contraindications. Belgium specified that oxytocin could only be used for induc-
tion of labour following administration of Prostin and a cervical Bishop Score �7. Five regi-
mens stated the maximum desired uterine activity. In Ireland’s national guideline, the rate of
infusion should be reduced if contractions exceeded 7 in any 15-minute interval in primipa-
rous women and 5 in 15 minutes in multiparous women. In Denmark, the rate of infusion
should be reduced if the frequency of contractions exceeded 5 in 10 minutes in primiparous
women, and Sweden’s guideline stated that the infusion rate should be reduced if the fre-
quency of contractions exceeded 5 per 10 minutes in both primiparous and multiparous
women. Additional restrictions applied in certain regimens, indicating a maximum overall
dose rather than a maximum dose rate. For example, the French-speaking region in Switzer-
land stopped escalation when the maximum overall dose of 10 IU was reached.
Start dose, escalation interval, escalation rate and maximum dose rate
Based on the details provided, we were able to calculate the start dose, escalation interval, esca-
lation rate and maximum dose rate increases of infused oxytocin on 16 regimens (Table 3).
Starting doses ranged from 0.06 IU/hour in Ireland’s and Poland’s minimum regimens to 0.90
IU/hour in Germany’s maximum regimen, and escalation intervals ranged from 15 to 60 min-
utes (Tables 4, 5, 6 and 7).
We were unable to perform calculations for Cyprus because variations in practices exist
between institutions, and between obstetricians, within the private and public sectors. We also
PLOS ONE Oxytocin infusion regimens
PLOS ONE | https://doi.org/10.1371/journal.pone.0227941 July 28, 2020 5 / 24
T
a
b
le
2
.
O
x
y
to
ci
n
in
fu
si
o
n
re
g
im
en
s.
C
o
u
n
tr
y
Is
th
er
e
a
n
a
ti
o
n
a
l
g
u
id
el
in
e?
Y
ea
r
O
x
y
to
ci
n
d
o
se
In
fu
si
o
n
fl
u
id
A
m
o
u
n
t
S
ta
rt
d
o
se
E
sc
a
la
ti
o
n
ra
te
M
a
x
im
u
m
d
o
se
Is
th
er
e
a
se
p
a
ra
te
g
u
id
el
in
e
fo
r
in
d
u
ct
io
n
a
n
d
a
cc
el
er
a
ti
o
n
(a
u
g
m
en
ta
ti
o
n
)
o
f
la
b
o
u
r?
Is
o
x
y
to
ci
n
ti
tr
a
te
d
w
it
h
u
te
ri
n
e
co
n
tr
a
ct
io
n
s?
H
o
w
o
ft
en
a
re
u
te
ri
n
e
co
n
tr
a
ct
io
n
s
re
co
rd
ed
?
A
u
st
ri
a
(I
n
st
it
u
ti
o
n
1
)
N
o
-
5
IU
0
.9
%
S
al
in
e
o
r
R
in
g
er
-
L
ac
ta
te
5
0
0
m
ls
9
m
ls
/h
o
u
r
9
m
ls
/h
o
u
r,
ev
er
y
2
0
m
in
u
te
s
-
N
o
Y
es
C
o
n
ti
n
u
o
u
sl
y
A
u
st
ri
a
(I
n
st
it
u
ti
o
n
2
)
N
o
-
5
IU
E
le
ct
ro
ly
ti
c
so
lu
ti
o
n
(e
.g
.,
E
L
O
-M
E
L
is
o
to
n
o
r
R
in
g
er
-
L
ac
ta
te
"F
re
se
n
iu
s"
)
5
0
0
m
ls
1
8
m
ls
/h
o
u
r
2
0
m
in
u
te
s
9
0
m
ls
/h
o
u
r
N
o
Y
es
C
o
n
ti
n
u
o
u
s
C
T
G
A
u
st
ri
a
(I
n
st
it
u
ti
o
n
3
)
N
o
-
5
IU
E
lo
-m
el
5
0
0
m
ls
1
8
m
ls
/h
o
u
r
6
m
ls
/h
o
u
r
1
2
0
m
ls
/h
o
u
r
Y
es
N
o
t
st
at
ed
C
o
n
ti
n
u
o
u
s
C
T
G
B
el
g
iu
m
(I
n
st
it
u
ti
o
n
)
N
o
2
0
1
7
1
0
IU
(1
m
IU
=
2
d
ro
p
s
(d
r)
)
G
lu
co
se
5
%
in
S
al
in
e
0
.4
5
%
1
0
0
0
m
ls
1
2
m
ls
/
h
o
u
rs
,
4
d
r/
m
in
u
te
,
2
m
U
/m
in
u
te
A
ft
er
2
0
m
in
u
te
s,
2
4
m
ls
/h
o
u
r,
8
d
r/
m
in
u
te
,4
m
U
;
A
ft
er
4
0
m
in
u
te
s,
3
6
m
ls
/h
o
u
r,
1
2
d
r/
m
in
u
te
,
6
m
U
;
A
ft
er
6
0
m
in
u
te
s,
5
4
m
ls
/h
o
u
r,
1
8
d
r/
m
in
u
te
,
9
m
U
;
A
ft
er
8
0
m
in
u
te
s,
8
4
m
ls
/h
o
u
r,
2
8
d
r/
m
in
u
te
,
4
m
U
;
A
ft
er
1
0
0
m
in
u
te
s,
1
2
0
m
ls
/h
o
u
r,
4
0
d
r/
m
in
u
te
,
2
0
m
U
;
A
t
1
2
0
m
in
u
te
s,
1
8
0
m
ls
/
h
o
u
r,
6
0
d
r/
m
in
u
te
,3
0
m
U
(o
n
ly
o
n
m
ed
ic
al
ad
v
ic
e)
1
2
0
m
ls
/h
o
u
r
o
r
2
0
m
U
/
m
in
u
te
=
2
m
ls
/
m
in
u
te
=
4
0
d
ro
p
s/
m
in
u
te
Y
es
Y
es
C
o
n
ti
n
u
o
u
s
m
o
n
it
o
ri
n
g
(C
on
tin
ue
d)
PLOS ONE Oxytocin infusion regimens
PLOS ONE | https://doi.org/10.1371/journal.pone.0227941 July 28, 2020 6 / 24
T
a
b
le
2
.
(C
o
n
ti
n
u
ed
)
C
o
u
n
tr
y
Is
th
er
e
a
n
a
ti
o
n
a
l
g
u
id
el
in
e?
Y
ea
r
O
x
y
to
ci
n
d
o
se
In
fu
si
o
n
fl
u
id
A
m
o
u
n
t
S
ta
rt
d
o
se
E
sc
a
la
ti
o
n
ra
te
M
a
x
im
u
m
d
o
se
Is
th
er
e
a
se
p
a
ra
te
g
u
id
el
in
e
fo
r
in
d
u
ct
io
n
a
n
d
a
cc
el
er
a
ti
o
n
(a
u
g
m
en
ta
ti
o
n
)
o
f
la
b
o
u
r?
Is
o
x
y
to
ci
n
ti
tr
a
te
d
w
it
h
u
te
ri
n
e
co
n
tr
a
ct
io
n
s?
H
o
w
o
ft
en
a
re
u
te
ri
n
e
co
n
tr
a
ct
io
n
s
re
co
rd
ed
?
B
el
g
iu
m
(F
o
o
d
a
n
d
D
ru
g
A
d
m
in
is
tr
a
ti
o
n
g
u
id
a
n
ce
)
N
o
2
0
1
4
1
0
IU
Is
o
to
n
ic
g
lu
co
se
so
lu
ti
o
n
1
IU
/1
0
0
m
ls
1
to
4
m
U
/
m
in
u
te
=
0
.1
to
0
.4
m
ls
/
m
in
u
te
(2
to
8
d
r/
m
in
u
te
)
P
ro
g
re
ss
iv
e
u
n
ti
l
d
es
ir
ed
ef
fe
ct
an
d
o
n
ly
if
fe
ta
l
h
ea
rt
ra
te
an
d
fr
eq
u
en
cy
an
d
d
u
ra
ti
o
n
o
f
th
e
co
n
tr
ac
ti
o
n
s
ar
e
m
o
n
it
o
re
d
cl
o
se
ly
.
If h
y
p
er
st
im
u
la
ti
o
n
o
f
th
e
u
te
ru
s
o
r
fe
ta
l
d
is
tr
es
s
o
cc
u
rs
,t
h
e
in
fu
si
o
n
sh
o
u
ld
b
e
st
o
p
p
ed
.I
f
af
te
r
in
fu
si
o
n
o
f
5
0
0
m
ls
n
o
re
g
u
la
r
co
n
tr
ac
ti
o
n
s
ar
e
o
b
se
rv
ed
,
in
d
u
ct
io
n
o
f
la
b
o
u
r
sh
o
u
ld
b
e
st
o
p
p
ed
.
1
2
0
m
l/
h
o
u
r,
o
r
2
0
m
U
/
m
in
u
te
=
2
m
ls
/
m
in
u
te
=
4
0
d
ro
p
s/
m
in
u
te
N
o
Y
es
C
lo
se
ly
C
y
p
ru
s
(i
n
st
it
u
ti
o
n
)
N
o
2
0
1
6
2
.5
IU
o
r
5
IU
H
ar
tm
an
s,
D
ex
tr
o
se
5
%
.
S
al
in
e
0
.9
%
5
0
0
m
ls
U
n
cl
ea
r
U
n
cl
ea
r
U
n
cl
ea
r
N
o
Y
es
E
ar
ly
fi
rs
t
st
ag
e
ev
er
y
1
5
m
in
u
te
s.
L
at
e
fi
rs
t
st
ag
e
ev
er
y
5
–
1
0
D
en
m
a
rk
(N
a
ti
o
n
a
l)
Y
es
,
o
n
au
g
m
en
ta
ti
o
n
o
f
la
b
o
u
r
o
n
ly
.
2
0
1
4
1
0
IU
0
.9
%
S
al
in
e
1
0
0
0
m
ls
3
.3
m
U
/
m
in
u
te
(2
0
m
ls
/h
o
u
r)
3
.3
m
U
/m
in
u
te
(2
0
m
ls
p
er
h
o
u
r)
ev
er
y
2
0
m
in
u
te
s
3
0
m
U
/
m
in
u
te
(1
8
0
m
ls
/
h
o
u
r)
G
u
id
el
in
e
o
n
au
g
m
en
ta
ti
o
n
o
f
la
b
o
u
r
o
n
ly
U
n
cl
ea
r.
T
h
er
e
is
n
o
m
en
ti
o
n
o
f
th
e
am
o
u
n
t
o
f
o
x
y
to
ci
n
in
fu
se
d
p
er
m
in
u
te
in
re
la
ti
o
n
to
co
n
tr
ac
ti
o
n
s.
H
o
w
ev
er
,t
h
e
g
u
id
el
in
e
st
re
ss
es
th
at
th
e
in
fu
si
o
n
sh
o
u
ld
o
n
ly
b
e
es
ca
la
te
d
u
n
ti
l
th
er
e
is
a
m
ax
im
u
m
o
f
5
co
n
tr
ac
ti
o
n
s
in
a
1
0
-m
in
u
te
in
te
rv
al
T
h
e
g
u
id
el
in
e
st
re
ss
es
th
at
th
er
e
sh
o
u
ld
b
e
n
o
m
o
re
th
an
5
co
n
tr
ac
ti
o
n
s
w
it
h
in
a
1
0
-m
in
u
te
in
te
rv
al
b
u
t
d
o
es
n
o
t
m
en
ti
o
n
an
y
sy
st
em
at
ic
re
co
rd
in
g
o
f
u
te
ri
n
e
co
n
tr
ac
ti
o
n
s
(C
on
tin
ue
d)
PLOS ONE Oxytocin infusion regimens
PLOS ONE | https://doi.org/10.1371/journal.pone.0227941 July 28, 2020 7 / 24
T
a
b
le
2
.
(C
o
n
ti
n
u
ed
)
C
o
u
n
tr
y
Is
th
er
e
a
n
a
ti
o
n
a
l
g
u
id
el
in
e?
Y
ea
r
O
x
y
to
ci
n
d
o
se
In
fu
si
o
n
fl
u
id
A
m
o
u
n
t
S
ta
rt
d
o
se
E
sc
a
la
ti
o
n
ra
te
M
a
x
im
u
m
d
o
se
Is
th
er
e
a
se
p
a
ra
te
g
u
id
el
in
e
fo
r
in
d
u
ct
io
n
a
n
d
a
cc
el
er
a
ti
o
n
(a
u
g
m
en
ta
ti
o
n
)
o
f
la
b
o
u
r?
Is
o
x
y
to
ci
n
ti
tr
a
te
d
w
it
h
u
te
ri
n
e
co
n
tr
a
ct
io
n
s?
H
o
w
o
ft
en
a
re
u
te
ri
n
e
co
n
tr
a
ct
io
n
s
re
co
rd
ed
?
G
er
m
a
n
y
(i
n
st
it
u
ti
o
n
)
(m
in
im
u
m
)
N
o
-
6
m
U
/m
l
R
in
g
er
so
lu
ti
o
n
5
0
0
1
5
m
U
/
m
in
u
te
1
5
m
U
/m
in
u
te
ev
er
y
2
0
m
in
u
te
s
6
0
m
U
/
m
in
u
te
N
o
t
st
at
ed
Y
es
C
o
n
ti
n
u
o
u
s
C
T
G
G
er
m
a
n
y
(I
n
st
it
u
ti
o
n
)
(m
a
x
im
u
m
)
N
o
-
6
0
m
U
S
al
in
e
0
.9
%
5
0
1
m
U
/
m
in
u
te
1
–
4
m
U
/m
in
u
te
ev
er
y
2
0
m
in
u
te
s
-
-
-
-
Ir
el
a
n
d
(N
a
ti
o
n
a
l
a
n
d
in
st
it
u
ti
o
n
)
Y
es
2
0
1
6
1
0
IU
0
.9
%
S
al
in
e
1
0
0
0
m
ls
1
–
5
m
U
/m
in
(6
–
3
0
m
ls
p
er
h
o
u
r)
1
–
5
m
U
/m
in
u
te
(6
–
3
0
m
ls
/h
o
u
r)
ev
er
y
1
5
–
3
0
m
in
u
te
s
3
0
m
U
/
m
in
u
te
(1
8
0
m
ls
/h
o
u
r)
N
o
Y
es
M
ea
su
re
d
o
v
er
1
5
-m
in
u
te
in
te
rv
al
s
It
a
ly
(I
n
st
it
u
ti
o
n
N
o
2
0
1
8
5
IU
0
.9
%
S
al
in
e
5
0
0
m
ls
5
IU
in
5
0
0
m
l
(1
0
m
U
/
m
l)
S
al
in
e
at
1
5
m
ls
/h
o
u
r
1
5
m
ls
/h
o
u
r
ev
er
y
1
5
m
in
u
te
s,
u
p
to
la
b
o
u
r
co
n
tr
ac
ti
o
n
s
o
f,
n
o
rm
al
ly
,3
st
ro
n
g
an
d
re
g
u
la
r
co
n
tr
ac
ti
o
n
s
la
st
in
g
ap
p
ro
x
.
1
m
in
u
te
in
1
0
m
in
u
te
s)
1
8
0
m
ls
/h
o
u
r
N
o
Y
es
C
o
n
ti
n
u
o
u
sl
y
,
v
ia
co
n
ti
n
u
o
u
s
m
o
n
it
o
ri
n
g
E
F
M
-C
T
G
N
o
rw
a
y
(N
a
ti
o
n
a
l)
Y
es
2
0
1
4
1
0
IU
0
.9
%
S
al
in
e
o
r
R
in
g
er
-
L
ac
ta
te
1
0
0
0
m
ls
5
m
U
/
m
in
u
te
(3
0
m
ls
/h
o
u
r)
2
.5
m
U
/m
in
u
te
ev
er
y
1
5
m
in
u
te
s
3
0
m
U
/
m
in
u
te
N
o
t
st
at
ed
Y
es
E
v
er
y
1
5
–
3
0
m
in
u
te
s,
al
w
ay
s
b
ef
o
re
in
cr
ea
si
n
g
d
o
se
P
o
la
n
d
(I
n
st
it
u
ti
o
n
)
N
o
2
0
1
7
5
IU
/m
l
0
.9
%
S
al
in
e,
G
lu
co
se
5
%
5
0
m
ls
5
IU
in
5
0
m
ls
S
al
in
e
at
0
.6
–
1
.2
m
ls
/
h
o
u
r
1
.2
m
ls
/h
o
u
r
ev
er
y
3
0
m
in
u
te
s,
u
p
to
re
g
u
la
r
co
n
tr
ac
ti
o
n
s
(n
o
rm
al
ly
3
st
ro
n
g
an
d
re
g
u
la
r
co
n
tr
ac
ti
o
n
s
la
st
in
g
ap
p
ro
x
.
1
m
in
u
te
in
1
0
m
in
u
te
s
1
8
m
ls
/h
o
u
r
N
o
Y
es
C
o
n
ti
n
u
o
u
sl
y
,
v
ia
co
n
ti
n
u
o
u
s
m
o
n
it
o
ri
n
g
C
T
G
(C
on
tin
ue
d)
PLOS ONE Oxytocin infusion regimens
PLOS ONE | https://doi.org/10.1371/journal.pone.0227941 July 28, 2020 8 / 24
T
a
b
le
2
.
(C
o
n
ti
n
u
ed
)
C
o
u
n
tr
y
Is
th
er
e
a
n
a
ti
o
n
a
l
g
u
id
el
in
e?
Y
ea
r
O
x
y
to
ci
n
d
o
se
In
fu
si
o
n
fl
u
id
A
m
o
u
n
t
S
ta
rt
d
o
se
E
sc
a
la
ti
o
n
ra
te
M
a
x
im
u
m
d
o
se
Is
th
er
e
a
se
p
a
ra
te
g
u
id
el
in
e
fo
r
in
d
u
ct
io
n
a
n
d
a
cc
el
er
a
ti
o
n
(a
u
g
m
en
ta
ti
o
n
)
o
f
la
b
o
u
r?
Is
o
x
y
to
ci
n
ti
tr
a
te
d
w
it
h
u
te
ri
n
e
co
n
tr
a
ct
io
n
s?
H
o
w
o
ft
en
a
re
u
te
ri
n
e
co
n
tr
a
ct
io
n
s
re
co
rd
ed
?
S
o
u
th
A
fr
ic
a
(N
a
ti
o
n
a
l)
Y
es
2
0
1
6
5
IU
R
in
g
er
s
L
ac
ta
te
1
0
0
0
m
ls
2
5
m
ls
/h
o
u
r
(2
U
/m
in
u
te
5
0
m
ls
/h
o
u
r
ev
er
y
3
0
m
in
u
te
s—
h
o
sp
it
al
g
u
id
el
in
es
:
d
o
u
b
le
ev
er
y
3
0
m
in
u
te
s:
st
ar
t
w
it
h
3
m
ls
fo
r
3
0
m
in
u
te
s,
th
en
6
m
ls
/h
o
u
r,
th
en
1
2
m
ls
/h
o
u
r,
th
en
2
4
m
ls
/h
o
u
r,
th
en
4
8
m
ls
/h
o
u
r,
th
en
6
0
m
ls
/h
o
u
r
af
te
r
3
0
m
in
u
te
s.
2
0
0
m
ls
/h
o
u
r
o
r
3
–
4
co
n
tr
ac
ti
o
n
s
>
4
0
se
co
n
d
s.
If
th
e
in
fu
si
o
n
ra
te
re
ac
h
es
2
0
0
m
ls
/h
o
u
r
an
d
st
ro
n
g
co
n
tr
ac
ti
o
n
s
ar
e
n
o
t
ac
h
ie
v
ed
,
in
cr
ea
se
th
e
d
o
se
b
y
st
ar
ti
n
g
an
in
fu
si
o
n
o
f
1
0
u
n
it
s
in
1
0
0
0
m
ls
at
1
5
0
m
ls
/h
o
u
r,
in
cr
ea
si
n
g
to
2
0
0
m
ls
/h
o
u
r
if
n
ec
es
sa
ry
.
N
o
Y
es
E
v
er
y
3
0
m
in
u
te
s
fo
r
1
0
m
in
u
te
s;
co
n
ti
n
u
o
u
s
C
T
G
,
if
av
ai
la
b
le
S
w
ed
en
(N
a
ti
o
n
a
l)
Y
es
2
0
1
1
5
IU
(8
.3
m
ic
ro
g
ra
m
/
m
l,
5
IU
/
m
l)
)
0
.9
%
S
al
in
e
5
0
0
m
ls
(o
r
2
m
ls
/1
0
0
0
m
ls
,
1
0
IU
/1
0
0
0
m
ls
),
(i
.e
.,
sa
m
e
co
n
ce
n
tr
at
io
n
b
u
t
in
5
0
0
o
r
1
0
0
0
m
ls
)
2
0
m
ls
/
h
o
u
r
In
cr
ea
se
w
it
h
2
0
m
ls
/h
o
u
r
ev
er
y
2
0
m
in
u
te
s
1
8
0
m
ls
/h
o
u
r
(c
an
b
e
ra
is
ed
af
te
r
th
at
b
u
t
af
te
r
d
o
ct
o
r’
s
o
rd
er
o
n
ly
)
N
o
Y
es
M
ea
su
re
d
o
v
er
1
0
m
in
u
te
s.
T
h
er
e
is
n
o
m
en
ti
o
n
o
f
h
o
w
o
ft
en
co
n
tr
ac
ti
o
n
s
sh
o
u
ld
b
e
re
co
rd
ed
b
u
t
it
st
at
es
th
at
th
er
e
sh
o
u
ld
al
so
b
e
a
sp
ec
ia
l
ch
ec
k
li
st
fo
r
o
x
y
to
ci
n
an
d
th
at
th
e
co
n
tr
ac
ti
o
n
s
sh
o
u
ld
b
e
n
o
te
d
ev
er
y
ti
m
e
th
e
o
x
y
to
ci
n
d
o
se
is
ch
an
g
ed
an
d
if
n
o
t
ch
an
g
ed
,
ev
er
y
h
o
u
r.
(C
on
tin
ue
d)
PLOS ONE Oxytocin infusion regimens
PLOS ONE | https://doi.org/10.1371/journal.pone.0227941 July 28, 2020 9 / 24
T
a
b
le
2
.
(C
o
n
ti
n
u
ed
)
C
o
u
n
tr
y
Is
th
er
e
a
n
a
ti
o
n
a
l
g
u
id
el
in
e?
Y
ea
r
O
x
y
to
ci
n
d
o
se
In
fu
si
o
n
fl
u
id
A
m
o
u
n
t
S
ta
rt
d
o
se
E
sc
a
la
ti
o
n
ra
te
M
a
x
im
u
m
d
o
se
Is
th
er
e
a
se
p
a
ra
te
g
u
id
el
in
e
fo
r
in
d
u
ct
io
n
a
n
d
a
cc
el
er
a
ti
o
n
(a
u
g
m
en
ta
ti
o
n
)
o
f
la
b
o
u
r?
Is
o
x
y
to
ci
n
ti
tr
a
te
d
w
it
h
u
te
ri
n
e
co
n
tr
a
ct
io
n
s?
H
o
w
o
ft
en
a
re
u
te
ri
n
e
co
n
tr
a
ct
io
n
s
re
co
rd
ed
?
S
w
it
ze
rl
a
n
d
F
re
n
ch
sp
ea
k
in
g
re
g
io
n
s
N
o
2
0
1
2
5
IU
0
.9
%
S
al
in
e
5
0
0
m
ls
3
0
m
ls
/h
o
u
r
1
5
m
ls
/h
o
u
r
ev
er
y
3
0
m
in
u
te
s.
If
th
er
e
ar
e
>
7
co
n
tr
ac
ti
o
n
s
in
1
5
m
in
u
te
s
th
en
n
o
fu
rt
h
er
es
ca
la
ti
o
n
3
6
0
m
ls
/h
o
u
r.
M
ax
im
u
m
to
ta
l
d
o
se
:
1
0
IU
N
o
Y
es
M
ea
su
re
d
o
v
er
1
5
-m
in
u
te
in
te
rv
al
s
S
w
it
ze
rl
a
n
d
G
er
m
a
n
a
n
d
It
a
li
a
n
sp
ea
k
in
g
re
g
io
n
s
N
o
2
0
1
2
5
IU
R
in
g
er
fu
n
d
in
B
ra
u
n
5
0
0
m
ls
1
2
m
ls
/h
o
u
r
1
2
m
ls
/h
o
u
r
ev
er
y
3
0
m
in
u
te
s.
If
th
er
e
ar
e
3
–
4
co
n
tr
ac
ti
o
n
s
in
1
0
m
in
u
te
s,
n
o
fu
rt
h
er
es
ca
la
ti
o
n
;
if
th
er
e
ar
e
>
4
co
n
tr
ac
ti
o
n
s
in
1
0
m
in
u
te
s,
re
d
u
ce
b
y
1
2
m
ls
/h
o
u
r
1
0
8
m
ls
/h
o
u
r
(0
.0
1
8
IU
/
m
in
),
to
b
e
ti
tr
at
ed
fo
r
a
m
ax
im
u
m
o
f
3
0
m
in
u
te
s
N
o
Y
es
M
ea
su
re
d
o
v
er
1
0
-m
in
u
te
in
te
rv
al
s
h
tt
p
s:
//
d
o
i.o
rg
/1
0
.1
3
7
1
/jo
u
rn
al
.p
o
n
e.
0
2
2
7
9
4
1
.t
0
0
2
PLOS ONE Oxytocin infusion regimens
PLOS ONE | https://doi.org/10.1371/journal.pone.0227941 July 28, 2020 10 / 24
calculated the total dose of oxytocin that would be infused if the infusion was escalated up to a
certain point (i.e., sufficient uterine contractions) and then maintained over an eight-hour
period, as a hypothetical labour duration. Calculations for the regimens that would lead to the
lowest and highest infused doses, Germany’s minimum and maximum regimens, are shown in
Tables 8 and 9 calculations for all regimens are presented as supporting information (S3 Data).
In the minimum regimen, the total dose infused would be 2.38 IU if the infusion was escalated
at each time point up to eight hours. In the maximum regimen, the total dose infused at one hour
and 20 minutes would be 2.70 IU if the infusion was increased for one hour and then maintained,
and the total dose infused over an eight-hour period would be 20.70 IU. If the infusion was esca-
lated for two hours and then maintained, the total dose infused over eight hours would be 27.00
IU. In Ireland’s minimum regimen, if the infusion was increased for one hour and then main-
tained for a further seven hours, the total dose infused would be 0.93 IU. If the infusion was esca-
lated at each interval, the total dose infused over eight hours would be 4.08 IU, more than four
times higher, but three times lower than the 13.28 IU that would be infused in the maximum
Table 3. Oxytocin infusion start dose, escalation interval, escalation rate and maximum dose rate.
Country Regimen source Regimen
type
Start Dose
Rate (mU/
hr)
Escalation
Interval
(Minutes)
Escalation
Rate (IU/hr)
Maximum Dose
Rate (IU/hr)
Ireland National Minimum 60 30 0.06 1.80
Institution Maximum 300 15 0.30 1.80
Italy Institution - 150 15 0.15 1.80
Cyprus Institution Minimum 175 60 0.18 0.90
Institution Maximum 350 60 0.35 1.80
Germany Institution Minimum 72 60 0.07 0.43
Institution Maximum 900 20 0.90 3.60
Switzerland German & Italian
speaking regions
- 120 30 0.12 1.08
French speaking
region
- 150 30 0.15 3.60
South
Africa
National - 125 30 0.25 1.00
Norway National - 300 15 0.15 1.80
Denmark National - 200 20 0.20 1.80
Sweden National - 200 20 0.20 1.80
Belgium Institution (no fixed
escalation rate)�
- 120 20 0.12 1.20
20 0.12 1.20
20 0.18 1.20
20 0.30 1.20
20 0.36 1.20
20 0.60 1.20
Belgium Food and Drug
Administration
guidance��
- 120 20 - 1.20
Austria Institution Minimum 90 20 0.09 0.90
Institution Maximum 180 20 0.06 1.20
Poland Institution Minimum 60 30 0.12 1.80
Institution Maximum 120 30 0.12 1.80
�No fixed escalation rate (IU/hr); after 120 minutes, seek medical advice before further escalation.
��See Table 2
https://doi.org/10.1371/journal.pone.0227941.t003
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regimen (S3 Data). The differences between the total doses infused in Poland’s and Austria’s min-
imum and maximum regimens would be much lower, 0.45 IU and 0.69 IU respectively.
The time when the maximum oxytocin infusion dose would be reached, assuming escala-
tion continued according to the regimen, is shown in Table 10.
Total amount of oxytocin IU infused
The total amount of oxytocin IU that would be infused over this hypothetical eight-hour was
highest in Germany’s maximum regimen (27.00 IU) and lowest in Germany’s minimum regi-
men (2.38 IU), and the variation was 24.62 IU (Table 10). Fig 2 shows the variations in cumu-
lative dose of oxytocin infused over eight hours, by regimen and country.
Discussion
Findings show considerable differences in the oxytocin regimens and escalation dose rates rec-
ommended in the 16 regimens reviewed, resulting in considerable variation in the total
Table 6. Regimens with 30-minute escalation interval.
Escalation interval (30 minutes) 00:00 00:30 01:00 01:30 02:00 02:30 03:00 03:30 04:00 04:30 05:00 05:30 06:00 06:30 07:00 07:30 08:00
Ireland (minimum)
Rate Escalation (IU/hr) --- 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Dose Rate (IU/hr) 0.06 0.12 0.18 0.24 0.30 0.36 0.42 0.48 0.54 0.60 0.66 0.72 0.78 0.84 0.90 0.96 1.02
Dose (IU) given at each time interval --- 0.03 0.06 0.09 0.12 0.15 0.18 0.21 0.24 0.27 0.30 0.33 0.36 0.39 0.42 0.45 0.48
Total Dose (IU) infused --- 0.03 0.09 0.18 0.30 0.45 0.63 0.84 1.08 1.35 1.65 1.98 2.34 2.73 3.15 3.60 4.08
Switzerland (German & Italian
Regions)
Rate Escalation (IU/hr) --- 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dose Rate (IU/hr) 0.12 0.24 0.36 0.48 0.60 0.72 0.84 0.96 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08
Dose (IU) given at each time interval --- 0.06 0.12 0.18 0.24 0.30 0.36 0.42 0.48 0.54 0.54 0.54 0.54 0.54 0.54 0.54 0.54
Total Dose (IU) infused --- 0.06 0.18 0.36 0.60 0.90 1.26 1.68 2.16 2.70 3.24 3.78 4.32 4.86 5.40 5.94 6.48
Switzerland (French Region)
Rate Escalation (IU/hr) --- 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Dose Rate (IU/hr) 0.15 0.30 0.45 0.60 0.75 0.90 1.05 1.20 1.35 1.50 1.65 1.80 1.95 2.10 2.25 2.40 2.55
Dose (IU) given at each time interval --- 0.08 0.15 0.23 0.30 0.38 0.45 0.53 0.60 0.68 0.75 0.83 0.90 0.98 1.05 1.13 1.20
Total Dose (IU) infused --- 0.08 0.23 0.45 0.75 1.13 1.58 2.10 2.70 3.38 4.13 4.95 5.85 6.83 7.88 9.00 10.20
South Africa
Rate Escalation (IU/hr) --- 0.25 0.25 0.25 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dose Rate (IU/hr) 0.13 0.38 0.63 0.88 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Dose (IU) given at each time interval --- 0.06 0.19 0.31 0.44 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
Total Dose (IU) infused --- 0.06 0.25 0.56 1.00 1.50 2.00 2.49 2.99 3.49 3.99 4.48 4.98 5.48 5.98 6.47 6.97
Poland (minimum)
Rate Escalation (IU/hr) --- 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12
Dose Rate (IU/hr) 0.06 0.18 0.30 0.42 0.54 0.66 0.78 0.90 1.02 1.14 1.26 1.38 1.50 1.62 1.74 1.80 1.80
Dose (IU) given at each time interval --- 0.03 0.09 0.15 0.21 0.27 0.33 0.39 0.45 0.51 0.57 0.63 0.69 0.75 0.81 0.87 0.90
Total Dose (IU) infused --- 0.03 0.12 0.27 0.48 0.75 1.08 1.47 1.92 2.43 3.00 3.63 4.32 5.07 5.88 6.75 7.65
Poland (maximum)
Rate Escalation (IU/hr) --- 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.00 0.00
Dose Rate (IU/hr) 0.12 0.24 0.36 0.48 0.60 0.72 0.84 0.96 1.08 1.20 1.32 1.44 1.56 1.68 1.80 1.80 1.80
Dose (IU) given at each time interval --- 0.06 0.12 0.18 0.24 0.30 0.36 0.42 0.48 0.54 0.60 0.66 0.72 0.78 0.84 0.90 0.90
Total Dose (IU) infused --- 0.06 0.18 0.36 0.60 0.90 1.26 1.68 2.16 2.70 3.30 3.96 4.68 5.46 6.30 7.20 8.10
https://doi.org/10.1371/journal.pone.0227941.t006
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amount of oxytocin IU that would be infused over eight hours of labour. The total amount of
oxytocin that would be infused was estimated at 27.00 IU in Germany’s maximum regimen, 11
Table 10. Time when maximum oxytocin infusion dose would be reached with maximum escalation.
No further escalation after this hour Time when maximum oxytocin infusion dose (IU) is
reached
1 2 3 4 5 6 7 8
Ireland (minimum) 0.93 1.74 2.43 3.00 3.45 3.78 3.99 4.08
Ireland (maximum) 9.15 13.28 13.28 13.28 13.28 13.28 13.28 13.28
Italy 4.58 8.55 11.93 11.93 11.93 11.93 11.93 11.93
Germany (minimum) 0.58 1.08 1.51 1.87 2.38 2.38 2.38 2.38
Germany (maximum) 20.70 27.00 27.00 27.00 27.00 27.00 27.00 27.00
Norway 5.78 9.75 12.34 12.34 12.34 12.34 12.34 12.34
Denmark 4.60 8.60 12.00 12.00 12.00 12.00 12.00 12.00
Sweden 4.60 8.60 12.00 12.00 12.00 12.00 12.00 12.00
Belgium 2.76 8.30 8.30 8.30 8.30 8.30 8.30 8.30
Austria (minimum) 2.07 3.87 5.82 5.85 5.85 5.85 5.85 5.85
Austria (maximum) 2.34 3.54 4.56 5.40 6.06 6.54 6.54 6.54
Switzerland (German & Italian speaking Regions) 1.86 3.48 4.86 6.00 6.48 6.48 6.48 6.48
Switzerland (French speaking Regions) 2.33 4.35 6.08 7.50 8.63 9.45 9.98 10.00
South Africa 2.88 6.25 6.97 6.97 6.97 6.97 6.97 6.97
Poland (minimum) 1.38 3.00 4.38 5.52 6.42 7.08 7.50 7.65
Poland (maximum) 1.86 3.48 4.86 6.00 6.90 7.56 7.98 8.10
IU/hour dose rates increases plateaued at two hours in three regimens, at three hours in five regimens and between
four and eight hours in the remaining regimens. The IU/hour dose rate increases had not plateaued at eight hours in
four regimens. The dose rate increase over an eight-hour period is presented graphically in Fig 1.
https://doi.org/10.1371/journal.pone.0227941.t010
Fig 1. Dose rate increase over an eight-hour period.
https://doi.org/10.1371/journal.pone.0227941.g001
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times higher than the 2.38 IU infused in their minimum regimen. In Ireland’s maximum regi-
men the total amount of oxytocin infused after eight hours was 13.28 IU, more than three
times higher than in their minimum regimen (4.08 IU). The total amount of oxytocin IU
infused in the other regimens ranged from 5.85 IU to 13.05 IU. Three regimens stipulated that
escalation of doses should cease when the desired number of uterine contractions in a specified
time period was reached, therefore it is possible that maximum doses are seldom, if ever,
reached in practice. Due to rate escalation differences, huge variations in the total dose infused
after eight hours were noted. However, it is important to note that dose escalation is contin-
ued/discontinued on clinical need, thus extreme outliers in dose administration will probably
be very rare. Of critical importance is that these regimens show a gradual increase in oxytocin
levels, even in the early stages of escalation, and lack the physiologically significant pulses of
oxytocin observed at increasing frequency during spontaneous labour [12]. While there is no
agreement on the most effective regimen or administration dose, it is reasonable to suggest
that the lowest possible effective amount should be administered to achieve the desired out-
come and avoid or minimise side effects related to the amount and speed of oxytocin adminis-
tered. This is vital in the context of the number of women worldwide who undergo induction
or augmentation of labour, irrespective of the indication, and receive intrapartum synthetic
oxytocin infusions, and current concern regarding over-medicalisation of normal labour and
birth [22].
Previous papers have reported variations in oxytocin regimens [24–27] and concluded that a
standardised administration regimen is needed. Our study shows that differences in regimens
persist, even within countries, and these differences result in considerable variations in the total
amount of oxytocin IU administered. Such variations in the total amount infused raise ques-
tions about the over-administration in some settings, especially if lower doses are effective and
when considered alongside worldwide rates of induction and acceleration of labour. For
Fig 2. Total oxytocin dose (IU) infused over an eight-hour period.
https://doi.org/10.1371/journal.pone.0227941.g002
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example, one study demonstrated that women spent 408 minutes on intravenous oxytocin fol-
lowing induction, and 321 minutes following augmentation, of labour [28]. They also found
that intravenous oxytocin titration was not recorded in 53% of the records reviewed. The pro-
portion of women whose labour was induced ranged from 22% in the United States of America
(USA) (2006) [3] and France (2016) [29] to 29.1% in New South Wales (NSW) (2007) [30] and
71.0% in Iran (2011–12) [22]. Proportions ranged from 6.8% in Lithuania to 33.0% in Wallonia
in 2010 [31] and from 18.6% to 45.7% in primiparous women across the 19 maternity hospitals/
units in Ireland in 2009 [32]. While the proportion of women whose labour was augmented
with oxytocin declined from 53% in 2001–02 to 26% 10 years later (2011–12) in the USA [33],
78.9% of women in India underwent labour augmentation with oxytocin in 2011 [22]. This lat-
ter proportion is, according to the authors, concerning and strongly suggestive of the routine
over-medicalisation of normal pregnancy and birth [22]. While synthetic oxytocin is a useful
medication, it is also dangerous when over or inappropriately used [34]. Short-term intrapar-
tum consequences of over or inappropriate use include myometrial hyperstimulation (excessive
frequency of contractions), hypertonicity (increased uterine tone between contractions), fetal
heart rate changes, fetal hypoxia etc. [1], and an analysis of litigation cases in Norway [20], Swe-
den [35] and the UK [19, 34] showed that the use of oxytocin played a role in many cases. This
financial burden to health services is of obvious importance but of concern are the conse-
quences for women, both physical and psychological. Research on the longer term effects of
synthetic oxytocin, during the postpartum period and beyond, is emerging and some studies
suggest that intrapartum synthetic oxytocin may alter the endogenous oxytocin system and
influence women’s stress, mood and behaviour [36]. At two months postpartum, women who
were breastfeeding exclusively had received significantly less infused synthetic oxytocin during
labour, compared with women who were not breastfeeding exclusively, and higher doses were
associated with greater depressive, anxious, and somatic symptoms [37]. Even within the first year
postpartum, exposure to peripartum synthetic oxytocin increased women’s risk of being diagnosed
with a postpartum depressive or anxiety disorder or being prescribed an antidepressant or anxio-
lytic medication [38]. Two of these studies did not mention the dose of oxytocin administered but
the average amount administered in the third study (36 IU) far exceeded the regimens presented in
our study. These three studies [36, 37, 38] did not differentiate between oxytocin administered
intrapartum or postpartum and different types of administration are likely to give rise to different
effects. In addition, the authors did not mention co-administration of epidural analgesia and other
medical interventions which may be associated with the effects caused by infused oxytocin. While
the results of these studies must be interpreted with caution, a plausible explanation for increased
levels of anxiety and depression is that the increased pain and stress experienced by women who
received high amounts of synthetic oxytocin led to higher stress levels, including higher levels of
cortisol, and that a sustained increase in stress levels was induced by infused oxytocin [13]. Never-
theless, it follows that it is preferable to infuse oxytocin at the lowest rate possible in order to avoid
hyperstimulation. In light of number of women who receive infused oxytocin during labour, and
the considerable variation in the total amount of IU infused, it is vital that women and their babies
are exposed to the minimum dose of a medication that alters the physiological processes and has
significant short and long-term consequences. It is also reasonable to assume that the variations in
regimens seen are, like other intrapartum interventions in high income countries (HICs) [39],
being driven by clinical practice patterns rather than medical indications.
Strengths and limitations
The strengths of this study lie in the comparison of 16 oxytocin infusion regimens sourced
from 12 countries. The study is innovative in that it moves beyond the regimens used to
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estimating the total amount of oxytocin IU that would be infused over an 8-hour period, and
results show an 11-fold difference between minimum and maximum amounts.
However, our study has some limitations. First, data on several regimens were taken
directly from written protocols, national, regional or institutional, and transcribed into the
data collection form but some were not, and there was no way of verifying data that were pro-
vided by these other means. Second, estimating the total amount of oxytocin IU infused by cal-
culating start dose and escalation dose rates from regimens ignores the obvious effect of
titration with uterine contractions. However, results show the wide variation in the total
amounts of oxytocin IU infused when maximum rates are reached and maintained over
defined time periods.
Conclusion
In the era of evidence-based health care, the fact that such widespread variation exists in the
use of infused oxytocin, and in the total amount infused, reflects potential overuse in many set-
tings. All maternity care professionals are driven by the need to reduce avoidable maternal and
neonatal morbidity and mortality, and it is crucial that intrapartum interventions designed to
reduce risk for some who have complications are not used routinely for others who are
healthy. It is also crucial that the total IU amount of a medication with known harmful side
effects is documented. Estimating the total amount of oxytocin IU received by women who
enter labour at term gestation, either spontaneously or following induction, documenting
titration rates and the institution’s mode of birth and neonatal outcomes may deepen our
understanding and be the way forward.
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